Kristen E. Muller
Papers
1
Total Citations
129
H-Index
1
About
Kristen E. Muller is a leading cancer researcher whose work centers on the development of oncolytic peptides and the induction of immunogenic cell death to combat tumors. Her most impactful contribution is the characterization of LTX-315, a cationic amphilytic peptide that selectively permeabilizes mitochondrial membranes, triggering a partially BAX/BAK1-regulated, caspase-independent necrosis. Crucially, her 2016 study (129 citations) demonstrated that intratumoral injection of LTX-315 not only destroys cancer cells directly but also stimulates a robust, T lymphocyte-mediated anticancer immune response. This dual mechanism—direct tumor lysis coupled with immune activation—positions LTX-315 as a promising candidate for immunotherapy combinations. Muller’s work has been instrumental in bridging oncolytic peptide therapy with immunology, offering a novel strategy to convert "cold" tumors into "hot," immune-sensitive ones. Her research continues to influence the design of next-generation cancer therapeutics, and her findings have been widely cited by groups exploring peptide-based immunotherapies and cell death pathways.
Research Focus
Key Achievements
Top Papers
- 1The oncolytic peptide LTX-315 triggers immunogenic cell death129 citations · 2016